-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the background of increasingly fierce competition in the pharmaceutical industry, a large number of pharmaceutical companies and medical companies are carrying out "self-help" through various forms, such as restructuring, laying off teams, and divesting business.
Among them, the sale and cancellation of subsidiaries have become the no.
It is reported that on January 12, 2022, Daiichi Sankyo announced that it will close all of its Plexxikon operations in South San Francisco, and the subsidiary will operate until the end of Mar.
Founded in 2001, Plexxikon is a subsidiary acquired by Daiichi Sankyo for US$935 million in 201 It already has two marketed anticancer drugs and six drugs that have already started clinical tria.
On February 16, Buchang Pharmaceutical also issued an announcement stating that, based on the current actual operating conditions and follow-up business development plans, the company decided to make its wholly-owned subsidiary in order to optimize resource allocation and organizational structure, reduce management costs, and improve operational management efficien.
Zhongxin Shunfa was cancell.
It is worth noting that in the news of announcing the cancellation and sale of subsidiaries, a group of companies also expressed that they will accelerate the expansion of other businesses through acquisitions and the establishment of wholly-owned subsidiari.
For example, on May 9, Jiangsu Hongyi Garden Construction Engineering .
, L.
(referred to as "Hongyi Garden") and Danyang Xintongqiu Optical Glasses .
, L.
respectively transferred the shares of Jiangsu Lerun Contact Lens .
, L.
to Yuyue Medic.
After the transfer, Yuyue Medical holds 100% of Lerun Contact Lens.
In fact, this is not the first acquisition by Yuyue Medical in the field of ophthalmolo.
Previously, Yuyue Medical also acquired the equity of Suzhou Liuliu Vision Technology and Jiangsu Shizhun at a price of 34223 million yuan and 42 million yuan respective.
On May 12, Saisheng Pharmaceutical issued an announcement stating that according to the company's strategic planning and business development needs, it held the 17th meeting of the fourth board of directors on May 12, 2022, and reviewed and approved the "Regulations on the Establishment of Foreign Investment.
"Proposal for a wholly-owned subsidiary", agreeing that the company will set up a wholly-owned subsidiary "Jilin Anniu Animal Husbandry Biotechnology .
, L.
" with its own capital of 100 million yuan (tentative name, the final business registration shall prevai.
This investment will promote the company to expand the development of biological breeding business fields such as breeding cattle, in vitro embryo technology application, and gene editing, and further promote the company's strategic layout in the fields of life science and general heal.
It is understood that Saisheng Pharmaceutical has begun to deploy innovative biological drugs several years ago, and has continuously invested over 100 million yu.
As early as July 23, 2019, Saisheng Pharmaceuticals planned to subscribe for 8225 million yuan of new registered capital of Green Bamboo Bio with 50 million yu.
After the capital increase, the company held 69% equity of Green Bamboo Bio; 50 million yuan to acquire a 278% stake in Puji Medici.
The investment in the establishment of a wholly-owned subsidiary is mainly based on strategic planning and future overall development considerations of Saisheng Pharmaceutic.
It is understood that the "14th Five-Year Plan" and the outline of the long-term goals for 2035 proposed that the integration and innovation of biotechnology and information technology will be promoted, and the development of biomedicine, biological breeding, biological materials, biotechnology services, and bioenergy industries will be accelerated, and the industry will become bigger and bigg.
Strong bioecono.
Therefore, it is generally believed in the industry that this foreign investment will provide more opportunities for the sustainable and steady development of Saisheng Pharmaceutical, which will help to improve the company's foreign investment income lev.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, the sale and cancellation of subsidiaries have become the no.
It is reported that on January 12, 2022, Daiichi Sankyo announced that it will close all of its Plexxikon operations in South San Francisco, and the subsidiary will operate until the end of Mar.
Founded in 2001, Plexxikon is a subsidiary acquired by Daiichi Sankyo for US$935 million in 201 It already has two marketed anticancer drugs and six drugs that have already started clinical tria.
On February 16, Buchang Pharmaceutical also issued an announcement stating that, based on the current actual operating conditions and follow-up business development plans, the company decided to make its wholly-owned subsidiary in order to optimize resource allocation and organizational structure, reduce management costs, and improve operational management efficien.
Zhongxin Shunfa was cancell.
It is worth noting that in the news of announcing the cancellation and sale of subsidiaries, a group of companies also expressed that they will accelerate the expansion of other businesses through acquisitions and the establishment of wholly-owned subsidiari.
For example, on May 9, Jiangsu Hongyi Garden Construction Engineering .
, L.
(referred to as "Hongyi Garden") and Danyang Xintongqiu Optical Glasses .
, L.
respectively transferred the shares of Jiangsu Lerun Contact Lens .
, L.
to Yuyue Medic.
After the transfer, Yuyue Medical holds 100% of Lerun Contact Lens.
In fact, this is not the first acquisition by Yuyue Medical in the field of ophthalmolo.
Previously, Yuyue Medical also acquired the equity of Suzhou Liuliu Vision Technology and Jiangsu Shizhun at a price of 34223 million yuan and 42 million yuan respective.
On May 12, Saisheng Pharmaceutical issued an announcement stating that according to the company's strategic planning and business development needs, it held the 17th meeting of the fourth board of directors on May 12, 2022, and reviewed and approved the "Regulations on the Establishment of Foreign Investment.
"Proposal for a wholly-owned subsidiary", agreeing that the company will set up a wholly-owned subsidiary "Jilin Anniu Animal Husbandry Biotechnology .
, L.
" with its own capital of 100 million yuan (tentative name, the final business registration shall prevai.
This investment will promote the company to expand the development of biological breeding business fields such as breeding cattle, in vitro embryo technology application, and gene editing, and further promote the company's strategic layout in the fields of life science and general heal.
It is understood that Saisheng Pharmaceutical has begun to deploy innovative biological drugs several years ago, and has continuously invested over 100 million yu.
As early as July 23, 2019, Saisheng Pharmaceuticals planned to subscribe for 8225 million yuan of new registered capital of Green Bamboo Bio with 50 million yu.
After the capital increase, the company held 69% equity of Green Bamboo Bio; 50 million yuan to acquire a 278% stake in Puji Medici.
The investment in the establishment of a wholly-owned subsidiary is mainly based on strategic planning and future overall development considerations of Saisheng Pharmaceutic.
It is understood that the "14th Five-Year Plan" and the outline of the long-term goals for 2035 proposed that the integration and innovation of biotechnology and information technology will be promoted, and the development of biomedicine, biological breeding, biological materials, biotechnology services, and bioenergy industries will be accelerated, and the industry will become bigger and bigg.
Strong bioecono.
Therefore, it is generally believed in the industry that this foreign investment will provide more opportunities for the sustainable and steady development of Saisheng Pharmaceutical, which will help to improve the company's foreign investment income lev.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
